Minretumomab is a type of drug used to treat cancer. It is a monoclonal antibody that works by targeting a protein found on the surface of certain types of cancer cells. Minretumomab is used to treat a type of cancer known as B-cell chronic lymphocytic leukemia (B-CLL). It can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. Minretumomab can help slow the growth and spread of cancer cells and improve the quality of life for people with B-CLL.
Minretumomab is a relatively new and specialized medication used to treat a specific type of cancer. Here's a breakdown of its key features:
Purpose:
- Treats acute lymphoblastic leukemia (ALL) that is either:
- Relapsed: Comes back after initial treatment.
- Refractory: Doesn't respond to standard treatment approaches.
How it Works:
- Belongs to a class of drugs called antibody-drug conjugates (ADCs).
- It targets a specific protein called CD19, found on the surface of most ALL cells.
- Minretumomab is an antibody attached to a chemotherapy drug.
- The antibody seeks out and binds to CD19 on leukemia cells.
- Once attached, the chemotherapy drug is delivered directly to the cancer cells, killing them.
Administration:
- Given by intravenous (IV) infusion into a vein, typically over a 30-minute period.
- Treatment is usually administered in cycles, with a specific number of doses given at intervals.
Important Considerations:
- Minretumomab is a complex medication with potentially severe side effects, so it's typically used in patients who haven't responded to other treatments.
- Common side effects include low blood cell counts, neurological problems, cytokine release syndrome (which can cause fever, chills, and trouble breathing), and infections.
- It's not suitable for everyone and can interact with other medications.
- Pregnant or breastfeeding women should not use Minretumomab.
Due to the potential risks and complexities involved, Minretumomab is only used in specialized healthcare settings by trained professionals.
Here are some additional resources you may find helpful:
- National Cancer Institute: Minretumomab: [invalid URL removed]
- Drugs.com: Minretumomab: [invalid URL removed]